

# **Repair of full-thickness cartilage defects using liposomal transforming growth factor-1**

Tomoyuki Abe<sup>1,2</sup>, Harumoto Yamada<sup>3</sup>, Hideto Nakajima<sup>2</sup>, Toshiyuki Kikuchi<sup>2</sup>, Hironari Takaishi<sup>1</sup>, TAKUSHI TADAKUMA<sup>4</sup>, KYOSUKE FUJIKAWA<sup>2</sup>, and YOSHIAKI TOYAMA<sup>1</sup>

<sup>1</sup> Department of Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan

<sup>2</sup> Department of Orthopaedic Surgery, National Defense Medical College, Tokorozawa, Japan

<sup>3</sup> Department of Orthopaedic Surgery, Fujita Health University, Toyoake, Japan

<sup>4</sup> Department of Parasitology and Immunology, National Defense Medical College, Tokorozawa, Japan

**Abstract** Transforming growth factor- $\beta$ 1 (TGF $\beta$ 1) is a wellknown, potent growth factor implicated in both in vitro and in vivo chondrogenesis. Liposomes have been employed as a drug delivery system to promote the efficient use of drugs. The objective of this study was to demonstrate that a single injection of liposomal  $TGF\beta1$  has an accelerating effect on the repair of an articular cartilage defect. Full-thickness articular cartilage defects were prepared on the patellar grooves of the femurs in knee joints of Japanese white rabbits. One week after surgery, various reagents including liposomal TGF $\beta$ 1, free TGF1, and phosphate-buffered saline were injected into the operated knee joints. At 3 weeks after surgery the specimens obtained from the lesions were evaluated histologically, and the glycosaminoglycan content was quantified. Histological examination revealed that the defects were filled with thicker fibrous cartilage and showed more intense metachromatic staining in the liposomal  $TGF\beta1$  group than in the other groups. The glycosaminoglycan content of the repair tissue was also significantly higher in the liposomal  $TGF\beta1$  group than in the other groups. This study indicated that the intraarticular injection of liposomal TGF $\beta$ 1 could accelerate the early-stage repair of full-thickness articular cartilage defects.

**Key words** Transforming growth factor  $(TGF)-\beta1$  · Fullthickness articular cartilage defects · Intraarticular injection · Liposomes

### **Introduction**

Articular cartilage is an important constituent of joints with various functions, including lubrication and absorption of shocks. Injury or destruction of the

Received: April 18, 2002/Accepted: September 4, 2002

articular cartilage results in deterioration of the joint. Accordingly, repairing such injured articular cartilage is extremely important to maintain adequate articular function. The repair of injured cartilage to a state that is as perfect as that of hyaline cartilage has been considered impossible. However, Brittberg et al. reported that when they implanted incubated autogenous cartilage cells at the site of a full-thickness cartilage defect the cartilage was restored to a condition that was histologically similar to the original hyaline cartilage.<sup>3</sup> A variety of attempts have also been made in basic and clinical settings to develop cultured chondrocytes and media that could be used to fill and repair cartilage defects.4

Many attempts have been made to accelerate the repair of articular cartilage injuries using non-invasive methods. These attempts have included single or repeated intraarticular injection of reagents that may promote restoration of the cartilage, such as growth factors. In particular, fibroblast growth factor-2 (FGF-2) has long been suggested as a strong mitogen for in vitro chondrogenesis. In a 1980 in vivo study, Wellmitz et al. injected FGF-2 intraarticularly into a joint with a cartilage defect in a rabbit model and found that FGF-2 effectively promoted cartilage restoration in both fullthickness and partial defects.28 FGF-2 has subsequently been studied at other institutions and is presently regarded as the most effective growth factor available for cartilage restoration.5,13 Insulin-like growth factor (IGF) has also been reported to be involved in chondrogenesis.25 In canine osteoarthritis models, Rogachefsky et al. found that intramuscular injection of sodium pentosan polysulfate (PPS) and IGF was effective therapy for osteoarthritis.20 Wakitani et al. made repeated intraarticular injections of hepatocyte growth factor (HGF), which has diverse biological activities, into full-thickness cartilage defects in a rabbit model, monitored a long-term (24 weeks) course, and reported a positive effect on restoration.27 Among these various

*Offprint requests to*: T. Abe, Department of Orthopaedic Surgery, Saiseikai-Utsunomiya Hospital, 911-1 Takebayashicho, Utsunomiya 321-0964, Japan

growth factors, transforming growth factor- $\beta$ 1 (TGF $\beta$ 1) has been suggested to play an important role in in vitro chondrogenesis. Glansbeek et al. reported that intraarticular injections of TGF $\beta$ 1 stimulated the replenishment of proteoglycans in arthritis models.<sup>9</sup> However, intraarticular injection of  $TGF\beta1$  has never been assessed using cartilage defect models.

Liposomes have been employed as a drug delivery system to promote the efficient use of drugs.18 The liposomes serve as carriers, allowing improved drug retention and reduced toxicity. They have also been applied in the field of gene therapy. Our former study showed that fluorescence (DiI) accumulated at the site of cartilage repair after intraarticular injection of fluorescence-labeled liposomes.<sup>1</sup> This observation suggested the possibility that the drug encapsulated into liposome had some positive effects on in vivo cartilage restoration.

We believe that efficient techniques for delivering drugs to promote the restoration of cartilage injuries are required to enable injured cartilage to be repaired noninvasively. In this study, we demonstrated that articular cartilage defects could be significantly restored after a single intraarticular injection of  $TGF\beta1$  using a liposome drug delivery system.

# **Materials and methods**

# *Preparation of full-thickness cartilage defects*

A total of 53 female Japanese white rabbits (2–3 months of age) (Tokyo Laboratory Animals Science, Tokyo, Japan), each weighing 2.5kg, were used in this study. The rabbits were anesthetized intravenously with sodium pentobarbital (25mg/kg). Following a medial parapatellar incision, the patella was dislocated laterally. A full-thickness defect (6mm long  $\times$  3mm wide) was created using a hand drill with a drill bit (3 mm in diameter) and a scalpel, which were passed through the articular cartilage into the subchondral bone of the patellar groove of the femur in the left knee joint. The depth of the defects was determined using a depth gauge; all defects were a uniform 3 mm in depth. The joints were irrigated with saline solution to remove any free cartilage and bone fragments. The joint capsule and skin were then sutured with monofilament nylon thread. Immobilization was not applied, and the rabbits were allowed to move freely in their cages after the surgery.

All rabbits were killed by intravenous administration of sodium pentobarbital 75 mg/kg. Altogether, 47 rabbits were used for histological evaluation or quantification of glycosaminoglycan (GAG) content. Six were used for histological evaluation of the

All surgical interventions were performed under sterile conditions. The rabbits were housed and maintained in accordance with the guidelines established by the National Institutes of Health Sciences.

# *Preparation of liposomes containing TGF1*

Liposomes were prepared from a lipid mixture of egg yolk phosphatidylcholine (egg-PC, 5µmol), cholesterol (Ch, 5µmol), and dipalmitoylphosphatidic acid (DPPA, 0.5µmol). The liposomes were negatively charged. The dried lipid film, obtained by rotary evaporation and subsequent vacuum desiccation, was dispersed in 0.1 or 0.2ml of phosphate-buffered saline solution (PBS), with or without human recombinant  $TGF\beta1$ (Amersham, Buckinghamshire, UK) at a dose of 100ng. When using these lipids, the rate of drugs trapped within the liposomes ranged from 10.3% to 16.2% (average 12.9%). The rate was determined using carcein (Wako, Tokyo, Japan), as described by Oku et al.<sup>17</sup>

# *Intraarticular injection of drugs*

The liposomal solution (0.2 ml) was resuspended in saline containing  $100$  ng TGF $\beta$ 1. One week after surgery this liposomal solution was injected into the surgically treated knee joints (lipo-TGF group). For the controls, PBS solution (PBS group), liposomal PBS solution without TGF $\beta$ 1 (lipo-PBS group), and PBS solution containing  $100$  ng TGF $\beta$ 1 (TGF group) were injected into the operated knee joints. Furthermore, a mixture of PBS solution  $(0.1 \text{ ml})$  with TGF $\beta$ 1  $(100 \text{ ng})$  and liposomal PBS solution  $(0.1 \text{ ml})$  without TGF $\beta$ 1 was injected into the knee as a control in which  $TGF\beta1$  was present but not encapsuled by the liposomes (non-lipo-TGF group). A preliminary experiment showed that cartilage restoration was optimal in the liposomal TGF $\beta$ 1 100 ng group compared to the liposomal TGF $\beta$ 1 10 ng and 500ng groups. A concentration of 100ng  $TGF\beta1$  was thus used as the most suitable dosage for cartilage repair in the present experiment.

These drugs and the short-term groups (3 weeks after surgery) are shown in Table 1 (each group:  $n = 7$ ). The histological evaluations of the long-term (12 weeks after surgery) were subsequently examined in the PBS, TGF, and lipo-TGF groups (each group:  $n = 4$ ).

# *Histological evaluation*

The knee joint was dissected, and the patellar groove of the femur was examined histologically. The proximal half of the repair tissue was used for histological

Group	Volume of $TGF-\beta1 (ng)$	Liposomes	Free TGF- $\beta$ 1	Encapsuled TGF- $\beta$ 1 in liposomes
<b>PBS</b>				
Lipo-PBS				
<b>TGF</b>	100			
Lipo-TGF	100			
Nonlipo-TGF	100			

**Table 1.** Groups of rabbits in the experiment

At 1 week after surgery, PBS containing these drugs was injected into the left knees of the rabbits PBS, phosphate-buffered soline; Lipo, liposome; TGF, transforming growth factor; +, drug contained TGF $\beta$ 1, liposomes, and TGF $\beta$ 1 encapsulated in liposomes;  $\overline{-}$ , drug contained none of the aforementioned substance

evaluation, and the distal half was used for quantification of the GAG content. The specimens from the distal part of the femur were fixed in 10% buffered formalin for 1 week. Each specimen was decalcified using Plank-Rychlo solution for 5 days, embedded in paraffin, cut into coronal sections, and then stained with toluidine blue. The sections were examined microscopically and scored according to the histological scoring method described by Wakitani et al.<sup>26</sup> (Table 2). The scoring data were "blindly" evaluated by the authors (T.A., H.N., T.K.).

# *Quantification of GAG content*

The GAG content was measured quantitatively using a 1,9-dimethylmethylene blue (DMB) assay and a fluorometric DNA assay. Papain (Sigma, St. Louis, MO, USA) was dissolved at a concentration of  $300\mu g/ml$  in a 50mM phosphate buffer (pH 6.5) with 5mM *N*acetylcysteine and 2 mM ethylenediaminetetraacetic acid (EDTA). After carefully sampling the distal part of the repaired tissue (from the superficial layer to the deep layer, without any subchondral bone or surrounding cartilage), the samples were immediately digested in a papain solution at 60°C for 16h.

A DMB assay was performed using the method described previously by Goldberg and Kolibas.10 Briefly, 140 µ of the sample was mixed 1:1 with DMB solution (Polysciences, Warrington, PA, USA) in a 96 well microtiter plate. The absorbance (530nm) was measured using a Titertek multiscan spectrophotometer (Labsystems, Helsinki, Finland). Standard curves were generated using a previously established concentration of chondroitin sulfate C (Seikagaku, Tokyo, Japan).

A fluorometric DNA assay of the samples was performed using the method described previously by Kim et al.<sup>14</sup> In a 96-well microtiter plate,  $15 \mu$ l of the papain-digested explants were mixed with 300µl of Hoechst 33258 dye (Polysciences). The emission and excitation spectra were determined at 365nm and 458nm, respectively. The fluorescence emission was

**Table 2.** Wakitani's histological scoring

Category	Points
Cell morphology	
Hyaline cartilage	0
Mostly hyaline cartilage	$\mathbf{1}$
Mostly fibrocartilage	2
Mostly noncartilage	3
Noncartilage only	$\overline{\mathcal{L}}$
Matrix staining (metachromasia)	
Normal (compared with host adjacent cartilage)	$^{(1)}$
Slightly reduced	1
Markedly reduced	$\overline{c}$
No metachromatic stain	$\overline{3}$
Surface regularity	
Smooth $(>\frac{3}{4})$	0
Moderate $(>1/2-3/4)$	$\mathbf{1}$
Irregular $(1/4-1/2)$	$\overline{c}$
Severely irregular $(<1/4)$	3
Thickness of cartilage	
>2/3	0
$1/3 - 2/3$	1
<1/3	2
Integration of donor with host adjacent cartilage	
Both edges integrated	0
One edge integrated	1
Neither edge integrated	$\mathfrak{D}$
Maximum total	

This table was extracted from Wakitani et al.'s histological grading scale<sup>26</sup>

measured using a Titertek multiscan spectrofluorometer. Standard curves were generated at a known concentration of calf thymus DNA (Sigma).

# *Immunohistochemistry of type II collagen*

Tissue specimens for immunohistochemistry and in situ hybridization of type II collagen mRNA were obtained from the PBS and lipo-TGF groups 3 weeks after surgery (each group,  $n = 3$ ). After being killed, the specimens were immediately fixed in 4% paraformaldehyde (Wako, Osaka, Japan) for 1 week. Each specimen was decalcified using 0.5M EDTA (pH 7.4) for 4 weeks, embedded in paraffin, and then cut into coronal sections.

The immunohistochemistry was performed as described by Nakajima et al.<sup>16</sup> The specific sections were deparaffinized and pretreated enzymatically with actinase E 0.1 mg/ml (Kaken, Tokyo, Japan) in PBS at 37°C for 30 min. The degree of nonspecific background staining was reduced by incubating the sections with a 1: 50 mixture of normal horse serum in PBS at room temperature for 60 min. The sections were incubated overnight with mouse anti-human type II collagen monoclonal antibody (50µg/ml in PBS containing 0.1% bovine serum albumin) (Fuji, Takaoka, Japan) at 4°C. The sections were then incubated with horse antimouse biotinylated immunoglobulin G (IgG) diluted 1: 200 with PBS (Vector Laboratories, Burlingame, CA, USA) for 60 min and with fluorescein streptavidine diluted 1:100 with PBS (Vector) at room temperature for 45 min.

# *In situ hybridization of type II collagen*

Linearized vectors containing a fragment of the type II procollagen C-peptide region were created using the method reported by Takaishi et al.<sup>24</sup> For the in situ hybridization, digoxygenin-labeled antisense or sense transcripts were generated from the linearized vectors by in vitro transcription using T7 or SP6 RNA polymerase and an RNA labeling kit (Boehringer-Mannheim, Mannheim, Germany). After transcription the DNA templates were removed by DNase treatment, and the labeled RNA transcripts were recovered after phenol-chloroform extraction and precipitation with ethanol prior to storage at  $-80^{\circ}$ C.

The sections were treated with proteinase K  $(20\mu$ g/ ml) at room temperature for 20 min, refixed in 4% paraformaldehyde, acetylated with acetic anhydride (0.25% in 0.1 M triethanolamine), washed again in PBS and distilled water, and then rehydrated. The sections were hybridized with antisense or sense riboprobes at 50°C for 16h. The hybridization buffer contained 50% formamide, 10% dextran sulfate, 10 mM dithiothreitol,  $200 \mu g/ml$  tRNA, and Denhardt's solution ( $\times 1$ ) in a humidified chamber. After hybridization, the tissue sections were washed in saline and sodium citrate buffer (SSC)  $(\times 1)/50\%$  formamide for 20 min at 45°C and then treated with RNase A 2µg/ml (in 10mM Tris-HCl, 0.5 M NaCl, and 1 mM EDTA) at 37°C for 30min. They were then washed in SSC  $(\times 2)$  and SSC  $(\times 0.2)$ , each at 37°C for 20 min. The immunological detection system, consisting of antibody conjugate and nitroblue tetrazolium chloride, was used according to the manufacturer's instructions (Boehringer-Mannheim).

#### *Statistical analysis*

The histological scores and GAG content were analyzed using the *F*-test. When the variance was equal, the data were further analyzed accordingly to Fisher's protected least significant difference. The difference was considered significant if  $P < 0.05$ .

# **Results**

# *Histological findings*

No signs of arthritis, such as osteophytes or severe synovial proliferation, were observed in any of the treated groups. Toluidine blue staining showed that the cartilage defects in six knees of the PBS group were filled with a thin, fibrous tissue that was involved in the convex and irregular surface and showed no or poor metachromasia. The nonintegrated gap between the surrounding cartilage and the repair tissue was visible (Fig. 1A). Under high-power magnification, the superficial and middle layers of the repair tissue showed an irregular extracellular matrix involving spindle-shaped cells resembling undifferentiated mesenchymal cells (Fig. 1A); the deep layer partially showed a fine extracellular matrix involving round, immature chondrocyte-like cells. Most specimens in the TGF group, the lipo-PBS group, and the non-lipo-TGF group also showed immature repair tissue similar to that seen in the PBS group.

On the other hand, in five specimens of the lipo-TGF group the defects were filled with a thick, relatively smooth-surfaced repair tissue resembling fibrocartilaginous tissue and also occasionally showed intense metachromasia in the middle and deep layers (Fig. 1B). The histological difference between the surrounding cartilage and the repair tissue was significantly recognizable. No tide marks were observed in any of the specimens. Under high-power magnification, the superficial layer of the repair tissue showed an irregular extracellular matrix and was involved with spindleshaped cells resembling undifferentiated mesenchymal cells. However, the middle and deep layers showed a fine extracellular matrix resembling fibrous cartilage and were involved with round, relatively mature chondrocyte-like cells (Fig. 1B).

## *Histological scoring of repair tissue*

The mean scores obtained using the Wakitani's histological scoring method are shown in Fig. 2. The total score for the lipo-TGF group was significantly better than the scores of all other groups ( $P < 0.05$ ). No significant differences were observed among the other groups, except for the lipo-TGF group. According to



**Fig. 1.** Histological findings 3 weeks after surgery using toluidine blue staining. **A** Phosphate-buffered saline (PBS) group. Cartilage defects were filled with thin, fibrous tissue with an irregular convex surface; they showed no or poor metachromasia. The nonintegrated gap between the surrounding cartilage and the repair tissue was visible.  $(\times 10)$  **B** Liposomal solution containing transforming growth factor (lipo-TGF) group. The defects were filled with a thick and relatively smooth-surfaced repair tissue resembling fibrocartilaginous tissue; it also occasionally showed intense

metachromasia in the middle and deep layers.  $(\times 150)$  **A,B** The middle layer in the central portion of the repair tissue is shown in the *squares*. (A'), PBS group. Middle layers of the repair tissue had an irregular extracellular matrix and were involved with spindle-shaped cells resembling immature mesenchymal cells. (*B'*), lipo-TGF group. Middle layers of the lipo-TGF group had a fine extracellular matrix resembling fibrous cartilage and were involved with round, relatively mature chondrocyte-like cells

the five categories evaluated by Wakitani's scoring system, a significant difference was observed only in the thickness scoring between the lipo-TGF group and all other treated groups ( $P < 0.05$ ). Moreover, significant differences were observed in the morphology and metachromasia between the lipo-TGF group and the other treated groups ( $P < 0.05$ ), except for the lipo-PBS  $group (morphology P = 0.1649, metachromasia P =$ 0.0997).

# *GAG content of the repair tissue*

The GAG content of the repair tissue was significantly higher in the lipo-TGF group than in all other groups  $(P < 0.05)$  (Fig. 3). No significant differences were observed among the other groups.

# *Immunohistochemistry of type II collagen and in situ hybridization of type II procollagen mRNA*

In an immunohistochemical analysis of type II collagen, all specimens in the PBS group and the lipo-TGF group showed no or weak staining in the central region of the superficial and middle layers (Fig. 4A,B). Only weak staining was observed in the extracellular matrix in the deep layer of the central portion of the PBS group (Fig. 4A). On the other hand, immunohistochemical assessment of the lipo-TGF group revealed intense





**Fig. 3.** Glucosaminoglycan (GAG) content of the repair tissue 3 weeks after surgery. A significant difference was observed between the lipo-TGF group and the other treatment groups ( $P < 0.05$  vs. all other groups)

staining of type II collagen only in the deep layer (Fig.  $4B'$ ).

During in situ hybridization of type II procollagen mRNA, no expression was observed in any cells of the superficial or middle layer of the PBS group (Fig. 5A). The PBS group showed weak signals only in the cells of the deep layer, suggesting that these cells may be chondrocytes or prechondrocytes (Fig. 5A'). On the other hand, samples from the lipo-TGF group showed positive expression in many cells of all layers, ranging from undifferentiated mesenchymal cells in the superficial layer to chondrocyte-like cells in the deep layer (Fig.  $5B$ , $B'$ ).

**Fig. 2.** Scoring for repair tissue 3 weeks after surgery. The mean scores were obtained using the histological scoring system described by Wakitani et al.26 Significant differences between the lipo-TGF group and the other treated groups are shown for the total scores  $(*P < 0.05$  vs.<br>all other groups). A significant other groups). A significant difference in thickness was observed between the lipo-TGF group and the other treated groups ( $\overline{P}$  < 0.05 vs. all other groups). Significant differences in morphology and metachromasia were also observed between the lipo-TGF group and all other treatment groups, except for the lipo-PBS group  $(**P < 0.05$  vs. TGF, nonlipo-TGF, and PBS groups)

# *Evaluation 12 weeks after surgery*

The cartilage defects in two or three specimens in all groups (PBS, TGF, and lipo-TGF groups) were filled with a thick, irregular-surfaced repair tissue involved with round chondrocyte-like cells, resembling fibrocartilaginous tissue. In two or three knees in the PBS and TGF groups, the repair tissue showed intense metachromasia only in the deep layer and an irregular extracellular matrix. On the other hand, in three specimens in the lipo-TGF group, the repair tissue showed intense metachromasia in the middle and deep layers and a fine extracellular matrix. The nonintegrated gap between the surrounding cartilage and the repair tissue was visible in all groups (Fig. 6).

# **Discussion**

Transforming growth factor- $\beta$ 1 is known to promote differentiation of mesenchymal stem cells into chondrocytes and to facilitate in vitro synthesis of matrix molecules, such as collagen, proteoglycan, and fibronectin.<sup>12,19,21,22</sup> Therefore, TGF $\beta$ 1 has long been proposed as a potential promoter of cartilage restoration. Hunziker and Rosenberg recently reported that they filled partial cartilage defects in the knee joints of  $r$ abbits using fibrin glue containing  $TGF\beta1$  liposomes and succeeded in restoring hyaline cartilage.<sup>11</sup> There have been no detailed reports on the effects of the intraarticular injection of  $TGF\beta1$  with regard to cartilage restoration in full-thickness defects.

The present study is the first demonstration of a noninvasive treatment using TGF<sub>1</sub> for cartilage restoration in full-thickness defects. We demonstrated in vivo that only  $TGF\beta1$  encapsulated into liposomes

**A**



**Fig. 4.** Immunohistochemical staining of type II collagen in the specimens from the PBS group and the lipo-TGF group 3 weeks after surgery. **A** Superficial and middle layers of the PBS group showed no or weak staining in the central region of the superficial and middle layers. **B** Superficial and middle

layers of the lipo-TGF group also showed no or weak staining. **A** Deep layer of the PBS group showed weak staining in the extracellular matrix. **B**' Deep layer of the lipo-TGF group showed intense staining in the extracellular matrix. **A–B**  $\times$ 200

has the ability to promote articular cartilage restoration. This promoting effect was quantitatively reflected by improving Wakitani's histological score; the total score of the lipo-TGF group, which was treated using liposome-encapsulated  $TGF\beta1$ , was significantly better than the scores of the other groups. In particular, the scores for metachromasia and cell morphology were better in the lipo-TGF group than in the other groups. The quantitative increase in the proteoglycan contents was also verified using the DMB method. Moreover, histologically, the repair tissue in most of the lipo-TGF specimens was thicker and contained many round chondrocyte-like cells in the middle and deep layers. These observations suggest that cartilage regeneration may be accelerated by the liposome-encapsulated  $TGF<sub>\beta</sub>1$ . The patterns of positive immunostaining and mRNA expression of type II collagen were recognized more often in the lipo-TGF group than in the PBS group. The positive immunostaining pattern and the mRNA expression of type II collagen in the deep layer, which is adjacent to the bone marrow, seem to indicate that liposome-encapsulated TGF<sub>β1</sub> activates migration of the mesenchymal cells from the bone marrow and their differentiation into chondrocytes, facilitating the synthesis of major matrix molecules such as proteoglycan and type II collagen. Our in vivo results showing positive immunostaining and the mRNA expression of type II collagen support the idea that  $TGF\beta1$  has the ability to facilitate synthesis of type II collagen in vitro.

The results of this study appear to be attributable to some of the advantages of using liposomes as the drug delivery system for cartilage restoration. The drug retention time in joints has been reported to increase considerably when drugs are encapsulated in liposomes. Bard et al. reported that the duration of 51Cr retention in joints intraarticularly injected with 51Cr encapsulated in liposomes was longer than when 51Cr was injected straight into the joints.<sup>2</sup> Foong and Green reported that



**Fig. 5.** In situ hybridization of type II collagen mRNA 3 weeks after surgery. **A** Superficial and middle layers of the PBS group: no expression in any cells. **B** Superficial and middle layers of the lipo-TGF group: positive expression in many undifferentiated mesenchymal cells in the superficial

the intraarticular retention time of labeled methotrexate could be elongated using liposomes.8 In the present study, we confirmed that cartilage restoration was accelerated only in the lipo-TGF group, suggesting that this acceleration can be partly explained by the prolonged duration of the intraarticular retention of TGF $\beta$ 1. The results of our former study — that fluorescence-labeled liposomes tend to accumulate at the site of cartilage repair — suggested one of the reasons liposomal TGF $\beta$ 1 had significant effects on in vivo cartilage restoration. The results appear to be attributable to the fact that liposomes tend to accumulate at sites of inflammation, possibly owing to the passive targeting property of liposomes.15,18 Liposome-encapsulated  $TGF\beta1$  may thus accumulate at the site of cartilage repair, where it can effectively promote cartilage restoration.

The timing of the intraarticular administration of  $TGF\beta1$  appears to be important for cartilage restoration. Shapiro et al. reported that cartilage defects in the

layer. A' Deep layer of the PBS group: weak signals only in the cells of the deep layer, suggesting that these cells may be chondrocytes or prechondrocytes. **B**' Deep layer of the lipo-TGF group: positive expression in many chondrocyte-like cells in the deep layer.  $\mathbf{A}-\mathbf{B}' \times 100$ 

superficial to deep layers could be filled with mesenchymal stem cells about 1 week after surgery.23 Because  $TGF\beta1$  could promote differentiation of mesenchymal stem cells into chondrocytes, the intraarticular administration of TGF $\beta$ 1 1 week after surgery may be effective in promoting cartilage restoration.

Dounchis et al. reported that  $TGF\beta1$  had a concentration-dependent effect on cell proliferation in vitro.6 Our preliminary data on the intraarticular injection of  $500 \text{ ng TGF} \beta1$ , even when encapsulated by liposomes, showed extensive fibroblastic hyperplasia involving the infiltration of inflammatory cells in the synovial membrane and poor cartilage restoration (data not shown): A massive intraarticular injection of TGF $\beta$ 1 has been reported to induce synovitis<sup>7</sup> and proteoglycan depletion. Moreover, our preliminary data on the intraarticular injection of 10ng TGF $\beta$ 1, even when encapsulated by liposomes, showed no difference in histological findings between the controls and the liposome-encapsulated group. It

 $\mathbf{A}$  , and a set of the set of  $\mathbf{B}$ 

**Fig. 6.** Histological findings 12 weeks after surgery. **A** PBS group. The defect was filled with a thick, irregular-surfaced repair tissue resembling fibrocartilaginous tissue. The repair tissue showed intense metachromasia only in the deep layer and an irregular extracellular matrix. A nonintegrated gap between the surrounding cartilage and the repair tissue was visible. **B** Lipo-TGF group. The cartilage defect was filled with

a thick, irregular-surfaced repair tissue with many round chondrocyte-like cells resembling fibrocartilaginous tissue. The repair tissue showed intense metachromasia in the middle and deep layers and a fine extracellular matrix. A nonintegrated gap between the surrounding cartilage and the repair tissue was also visible. **A,B** toluidine blue  $\times 10$ 

appears that the dose of  $TGF\beta1$  is important for cartilage restoration and that  $TGF\beta1$  has a positive in vivo influence on chondrogenesis with a suitable range of concentrations.

Our data for the 12-week study showed no significant difference between the controls and the lipo-TGF group in regard to cartilage regeneration. Moreover, our preliminary data at 24 weeks showed that the repair tissue in both groups showed imperfect and degenerative fibrous cartilage (data not shown). These long-term results suggest the limited usefulness of liposomes as a drug delivery system and the difficulty of achieving cartilage restoration by the intraarticular administration of TGF $\beta$ 1.

# **Conclusions**

The present observations indicate that intraarticular administration of TGF $\beta$ 1 accelerates the repair of fullthickness articular cartilage defects. This is the first report showing that the intraarticular administration of TGFβ1 effectively promotes cartilage regeneration in a cartilage defect model. Furthermore, the use of liposomes enabled  $TGF\beta1$  to act efficiently on cartilage regeneration in the short term. However, our data from a long-term follow-up study suggest that cartilage regeneration is difficult using liposomal TGF $\beta$ 1. Consequently, more sophisticated drug delivery systems and more effective drugs with no side effects must be developed for perfect cartilage restoration.

*Acknowledgments.* We express our deep appreciation to Professor Yutaka Yabe for providing the opportunity to perform this study.

# **References**

- 1. Abe T, Yamada H, Nakajima H, et al. Accelerated repair of fullthickness articular cartilage defects with single intraarticular injection of liposomal transforming growth factor  $\beta$ 1. Trans Orthop Res Soc 1998;23:380.
- 2. Bard DR, Knight CG, Thomas DPP. The retention and distribution in the rabbit knee of a radionuclide complexed with a lipophilic chelator in liposomes. Clin Exp Rheumatol 1983;1:113–7.
- 3. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994;331:889–95.
- 4. Buckwalter JA, Mankin HJ. Articular cartilage repair and transplantation. Arthritis Rheum 1989;41:1331–42.
- 5. Cuevas P, Burgos J, Baird A. Basic fibroblast growth factor (FGF) promotes cartilage repair in vivo. Biochem Biophys Res Commun 1988;156:611–8.
- 6. Dounchis JS, Goomer RS, Harwood FL, et al. Chondrogenic phenotype of perichondrium-derived chondroprogenitor cells is influenced by transforming growth factor beta-1. J Orthop Res 1997;15:803–7.
- 7. Elford PR, Graeber M, Ohtsu H, et al. Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon intraarticular injection of transforming growth factor  $\beta$ -2 in the rabbit. Cytokines 1992;4:232–8.
- 8. Foong WC, Green KL. Retention and distribution of liposomeentrapped [3 H] methotrexate injected into normal or arthritic rabbit joints. J Pharm Pharmacol 1988;40:464–8.
- 9. Glansbeek HL, van Beuningen HM, Vitters EL, et al. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor- $\beta$  into murine knee joints. Lab Invest 1998;78:133–42.
- 10. Goldberg RL, Kolibas LM. An improved method for determining proteoglycans synthesized by chondrocytes in culture. Connect Tissue Res 1990;24:265–75.
- 11. Hunziker EB, Rosenberg L. Induction of repair in partial thickness articular cartilage lesions by timed release of TGF $\beta$ . Trans Orthop Res Soc 1994;19:236.
- 12. Ignotz RA, Massague J. Transforming growth factor  $\beta$ stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337–45.
- 13. Jentzsch KD, Wellmitz G, Heder G, et al. A bovine brain fraction with fibroblast growth factor activity inducing articular cartilage regeneration in vivo. Acta Biol Med Germ 1980;39:967–71.
- 14. Kim Y-J, Sah RLY, Doong J-Y, et al. Fluorometric assay of DNA in cartilage explants using Hoechst 33258. Anal Biochem 1988;174:168–76.
- 15. Love WG, Amos N, Kellaway IW, et al. Specific accumulation of technetium-99 m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: effects of liposome size. Ann Rheum Dis 1989;48:143–8.
- 16. Nakajima H, Goto T, Horikawa O, et al. Localization of carboxyterminal type II procollagen peptide (pCOL-II-C) and type II collagen in the repair tissue of full-thickness articular cartilage defect. Connect Tissue Res 1998;37:195–204.
- 17. Oku N, Kendall DA, Macdonald RC. A simple procedure for the determination of the trapped volume of liposomes. Biochim Biophys Acta 1982;691:332–40.
- 18. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1987;46:1576–87.
- 19. Redini F, Galera P, Mauviel A, et al. Transforming growth factor  $\beta$  stimulates collagen and glycosaminoglycan biosynthesis in

cultured rabbit articular chondrocytes. FEBS Lett 1988;234:172– 6.

- 20. Rogachefsky RA, Dean DD, Howell DS, et al. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate. Osteoarthritis Cartilage 1993;1:105– 14.
- 21. Rosen DM, Stempien SA, Thompson AY, et al. Differentiation of rat mesenchymal cells by cartilage-inducing factor. Exp Cell Res 1986;165:127–38.
- 22. Seyedin SM, Thompson AY, Bentz H, et al. Cartilage-inducing factor-A. J Biol Chem 1986;261:5693–5.
- 23. Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J Bone Joint Surg Am 1993;75:532–53.
- 24. Takaishi H, Nemoto O, Shiota M, et al. Type-II collagen gene expression is transiently upregulated in experimentally induced degeneration of rabbit intervertebral disc. J Orthop Res 1997;15:528–38.
- 25. Trippel SB, Corvol MT, Dumontier MF, et al. Effect of somatomedin-C/insulin-like growth factor I and growth hormone on cultured growth plate and articular chondrocytes. Pediatr Res 1989;25:76–82.
- 26. Wakitani S, Goto T, Pineda SJ, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am 1994;76:579–92.
- 27. Wakitani S, Imoto K, Kimura T, et al. Hepatocyte growth factor facilitates cartilage repair: full thickness articular cartilage defect studied in rabbit knees. Acta Orthop Scand 1997;68:474–80.
- 28. Wellmitz G, Petzold E, Jentzsch KD, et al. The effect of brain fraction with fibroblast growth factor activity on regeneration and differentiation of articular cartilage. Exp Pathol 1980;18:282–7.